terça-feira, abril 19, 2005

As benesses da indústria farmacêutica

The power of drug companies to buy influence over every key group in healthcare-doctors, charities, patient groups, journalists, politicians-has clearly shocked a UK parliamentary committee (p 855). It should shock us all. Can we console ourselves that companies' lavish spending on research and marketing, which far outstrips spending on independent research and drug information, leads to truly innovative treatments? No, says the committee's report. Can we rely on regulatory bodies to keep the industry in check? No, again.

Comments: Enviar um comentário

<< Home

This page is powered by Blogger. Isn't yours?

Enter your email address below to subscribe to Blog do GAT!

powered by Bloglet